CDT vs. TSVT, PBYI, ELYM, ALDX, MACK, QURE, OMER, FHTX, GTHX, and OVID
Should you be buying Conduit Pharmaceuticals stock or one of its competitors? The main competitors of Conduit Pharmaceuticals include 2seventy bio (TSVT), Puma Biotechnology (PBYI), Eliem Therapeutics (ELYM), Aldeyra Therapeutics (ALDX), Merrimack Pharmaceuticals (MACK), uniQure (QURE), Omeros (OMER), Foghorn Therapeutics (FHTX), G1 Therapeutics (GTHX), and Ovid Therapeutics (OVID). These companies are all part of the "pharmaceutical preparations" industry.
Conduit Pharmaceuticals (NASDAQ:CDT) and 2seventy bio (NASDAQ:TSVT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, dividends, valuation, risk, community ranking, profitability, earnings and analyst recommendations.
Conduit Pharmaceuticals has a net margin of 0.00% compared to 2seventy bio's net margin of -313.51%. Conduit Pharmaceuticals' return on equity of 0.00% beat 2seventy bio's return on equity.
In the previous week, 2seventy bio had 14 more articles in the media than Conduit Pharmaceuticals. MarketBeat recorded 15 mentions for 2seventy bio and 1 mentions for Conduit Pharmaceuticals. Conduit Pharmaceuticals' average media sentiment score of 1.89 beat 2seventy bio's score of 0.04 indicating that Conduit Pharmaceuticals is being referred to more favorably in the media.
3.3% of Conduit Pharmaceuticals shares are owned by institutional investors. Comparatively, 93.9% of 2seventy bio shares are owned by institutional investors. 23.5% of Conduit Pharmaceuticals shares are owned by insiders. Comparatively, 2.6% of 2seventy bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
2seventy bio has a consensus target price of $12.86, suggesting a potential upside of 167.30%. Given 2seventy bio's higher probable upside, analysts plainly believe 2seventy bio is more favorable than Conduit Pharmaceuticals.
2seventy bio received 25 more outperform votes than Conduit Pharmaceuticals when rated by MarketBeat users.
Conduit Pharmaceuticals has a beta of 2.52, meaning that its share price is 152% more volatile than the S&P 500. Comparatively, 2seventy bio has a beta of 1.87, meaning that its share price is 87% more volatile than the S&P 500.
Conduit Pharmaceuticals has higher earnings, but lower revenue than 2seventy bio.
Summary
Conduit Pharmaceuticals and 2seventy bio tied by winning 7 of the 14 factors compared between the two stocks.
Get Conduit Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CDT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CDT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Conduit Pharmaceuticals Competitors List
Related Companies and Tools
